Poltreg S.A. (WSE:PTG)

Market Cap	114.72M -33.5%
Revenue (ttm)	n/a -75.0%
Net Income	-24.56M
EPS	-5.27
Shares Out	4.66M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,202
Average Volume	2,926
Open	24.80
Previous Close	24.60
Day's Range	24.60 - 25.00
52-Week Range	22.70 - 39.00
Beta	0.73
RSI	48.69
Earnings Date	Apr 16, 2026

About Poltreg

Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases. It engages in the development of therapies for the treatment of type 1 diabetes in children, as well as multiple sclerosis. The company was incorporated in 2016 and is based in Gdańsk, Poland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 33
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: PTG

Financial Performance

In 2024, Poltreg's revenue was 350,000, a decrease of -74.98% compared to the previous year's 1.40 million. Losses were -18.71 million, 38.1% more than in 2023.